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Misfoding and amyloid aggregation of intrinsically disordered proteins (IDPs) are 
implicated in a variety of diseases. Studies have shown that membrane plays important roles on 
the formation of intermediate structures of IDPs that can initiate (and/or speed-up) amyloid 
aggregation to form fibers. The process of amyloid aggregation also disrupts membrane to 
cause cell death in amyloid diseases like Alzheimer’s disease and type-2 diabetes. On the other 
hand, recent studies reported the membrane fusion properties of amyloid fibers. Remarkably, 
amyloid-fibril formation by short peptide fragments of highly abundant prostatic 
acidic-phosphatase (PAP) in human semen and are capable of boosting the rate of HIV 
infection up to 400,000-fold during sexual contact. Unlike the least toxic fully matured fibers 
of most amyloid proteins, the Semen-derived Enhancer of Virus Infection (SEVI) 
amyloid-fibrils of PAP peptide fragments are highly potent in rendering the maximum rate of 
HIV infection. This unusual property of amyloid fibers has witnessed increasing number of 
studies on the biophysical aspects of fiber formation and fiber-membrane interactions. NMR 
studies have reported a highly disordered partial helical structure in a membrane environment 
for the intrinsically disordered PAP peptide that promotes the fusion of the viral membrane 
with that of host cells. The purpose of this review article is to unify and integrate biophysical 
and immunological research reported in the previous studies on SEVI. Specifically, amyloid 
aggregation, dramatic HIV infection enhancing properties, membrane fusion properties, high 
resolution NMR structure, and approaches to eliminate the enhancement of HIV infection of 
SEVI peptides are discussed. 
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HIV infections continue to be a major health issue 
The human immunodeficiency virus (HIV), a causative agent in acquired 
immunodeficiency syndrome (AIDS), was first detected in the 1980s.1-3 AIDS is amongst the 
top ten fatal diseases worldwide, and, seriously, has killed more than 25 million people.3 33 
million people still suffer from HIV-induced AIDS, in particular, in the developing countries: 
approximately 90% of children and approximately 68% of all adults are infected with HIV in 
sub-Saharan Africa. One out of 200-2,000 coital acts results in infection, indicating markedly 
low sexual infection of HIV virions.4 However, high viral titers that occur during acute 
transmission accelerate the infection rate by approximately 10-fold.5 Although the 
concentration of virus particles in seminal fluid is important, semen itself was a key 
modulator of HIV transmissibility, and enhanced actually the infection of 
physiologically-relevant cell types.6,7 Thus, certain natural cofactors in the ejaculate have 
been implicated to serve as HIV transmission by enhancing the efficiency of viral infectivity.6 
 
SEVI amyloid dramatically increases the rate of HIV infection up to 400,000 times 
Innovative studies based on screening, mass spectrometry, and sequencing of a library 
of all seminal (poly)peptides clarified that one fraction enhanced remarkably HIV 
infectivity.6 It was eventually elucidated that a proteolytic fragment of prostatic acid 
phosphatase (PAP),8 which exists in seminal fluid at approximately 1-2 mg ml-1, 
corresponded to residues 248-286 of PAP (PAP248-286). Intriguingly, soluble synthetic 
PAP248-286 peptide was incapable of potentiating HIV infection, however, aggregated 
PAP248-286 did augment viral infectivity by up to five orders of magnitude.
6 These PAP248-286 
aggregates were found to be typical amyloid fibrils, one type of insoluble protein aggregates, 
on the basis of tinctorial properties of thioflavin T (ThT) and congo red dyes as well as 
cross-β structures of X-ray fiber diffraction (strong reflections at 4.7 and 10.6 Å), and thus 
are termed semen-derived enhancer of viral infection (SEVI). 
A 39-amino acid fragment of PAP248-286, SEVI precursor, contains approximately 20% 
of positively-charged residues with a theoretical pI of 10.2.3 Dual binding capability of SEVI 
amyloid fibrils to acidic (negatively-charged) surfaces of the HIV virion and host cell9 was 
attributable to cationic surfaces of SEVI amyloids. Thus, SEVI amyloids were implicated to 
function as a connecter between virions and host cells using attractive electrostatic 
interactions by minimizing repulsive forces between virions and host cells [Fig. 1(A)],9,10 and 
thereby promoting fusion of virion. In line with this hypothesis, SEVI amyloid fibrils, formed 
from a PAP248-286 mutant with positive charges neutralized, largely reduced HIV 
transmission.9 All these results suggested SEVI amyloid-mediated enhancement of HIV 
infection.  
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Protein misfolding and amyloid aggregation implicated in amyloid diseases 
Amyloid fibrils are best studied protenious fibrillar aggregates as their formation is 
deeply responsible for more than 40 diseases such as Alzheimer`s and Parkinson`s diseases 
and type-2 diabetes.11-13 Mature amyloid fibrils consist of several protofillaments containing 
β-sheets which are predominantly stabilized by a number of intermolecular hydrogen bonds 
among constituent monomers as revealed by several biophysical experiments.11,14-17 
Spontaneous amyloid fibrillation shows generally the two-step reaction [Fig. 1(B)]. Amyloid 
fibrils grow rapidly following nucleation which produces the lag time. Thus, the addition of 
preformed short amyloid fibrils to monomer solutions as seeds skips the lag phase and solely 
shows the elongation phase, in seeded amyloid formation. Other types of aggregates such as 
amorphous aggregates, oligomers, and protofibrils are also detected as on- or off-pathway 
intermediates. 
Recent studies have proposed that solubility and supersaturation are fundamental 
factors in understanding protein aggregation in solution.18-25 Proteins over the solubility limit 
must form insoluble aggregates such as amyloid fibrils from the thermodynamic point of 
view. However, apparently soluble proteins prior to the phase transition to insoluble solid 
states are often detected due to kinetic trapping by the metastability of supersaturation, which 
is certainly linked to the cause and effect relationship with the nucleation and lag time. Other 
factors such as biological membranes, hydrophobic surfaces, or agitation/cavitation have 
shown to promote amyloid formation by disrupting the metastability of supersaturation. 
Among these, the cell membrane components play crucial roles in the formation of 
intermediate nucleating structures, kinetics of aggregation, and the generation of polymorphic 
fibers. Remarkably, the process of amyloid aggregation itself disrupts the cell membrane to 
execute cell toxicity in various amyloid diseases. This process of amyloid-induced cell death 
is implicated in the loss of neuronal cells by the aggregating amyloid-β (Aβ) and other 
amyloid proteins in Alzheimer’s disease and in the killing of insulin-producing islet cells by 
islet amyloid polypeptide (IAPP, or also known as amylin).13,26,27 
SEVI precursors also showed nucleation-dependent two-step amyloid formation under 
several different conditions;6,28-33 however, much still remains to be investigated, for instance, 
detailed aggregation kinetic analysis and cross-seeding effects on SEVI amyloid formation. 
Atomistic and secondary structure and morphology of SEVI amyloid fibrils were 
characterized using X-ray crystallography, circular dichroism (CD) spectroscopy, Fourier 
transform infrared spectroscopy, NMR spectroscopy, transmission electron microscopy 
(TEM).6,15,34,35 On the one hand, some specific precursor structures of proteins such as 
α-synuclein, β2-microglobulin, SH3 domain, lysozyme, and insulin have been suggested to 
be amyloidogenic,20,21,36-39 which convinces the consequence of the structural study in 
understanding amyloidogenesis from the microscopic point of view. Although the 
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residue-based amyloidogenic propensity of SEVI precursors was examined,32 high-resolution 
structural studies of SEVI precursor at various conditions are essential for deeper 
understanding of the molecular mechanism of SEVI amyloid formation, effects of SEVI on 
membranes of the HIV virion and host cell, and structure-based inhibitor development. 
We herein describe our recent studies on NMR structures of intrinsically disordered 
and partially helical SEVI precursors in solution as well as on SEVI-induced membrane 
fusion for the remarkable enhancement of HIV infection based on high-resolution structures. 
Effects of cross seeding of amyloid fibrils of bacterial curli proteins on SEVI amyloid 
generation will also be addressed. Finally, a series of strategies for suppression, prevention, 
elimination of SEVI amyloid fibril-enhanced HIV viral activity are comprehensively 
surveyed and suggested. 
 
SEVI induced membrane fusion is key for dramatic enhancement of HIV 
infection 
Since in-vivo studies have demonstrated a dramatic enhancement of HIV infection in 
the presence of SEVI amyloid aggregates, it is very important to understand the mechanism by 
which SEVI executes its role. Although there are numerous factors in-vivo that can contribute 
to the effect of SEVI on HIV infection, the exact mechanism of SEVI-enhanced viral infection 
was unclear from in-vivo studies. In-vitro experimental evidences have suggested that a 
synthetic SEVI peptide freshly prepared is ineffective in promoting viral infection whereas the 
aggregated forms of SEVI were found to exhibit the maximum enhancement of viral infection. 
Studies have focused on understanding the factors that influence the aggregation kinetics and 
fibril formation of intrinsically disordered SEVI peptides. For example, in-vitro studies 
focused on evaluating the roles of pH, temperature, peptide concentration, mechanical force, 
metal ions, membrane, lipid charge, salt, and also the presence of bacterial curli fibers. 
By using synthetic lipid bilayers as model cellular membrane, a biophysical study 
investigated the membrane fusion by SEVI as a mechanism for the observed viral binding and 
entry into host cells. An interesting observation was that freshly dissolved monomers of SEVI 
induced membrane disruption with a maximum effect for lipid membranes containing 
maximum anionic lipids and aggregation of liposomes at acidic pH but not at neutral pH (Fig. 
2). This in-vitro experimental finding correlated well with SEVI’s ability to enhance viral 
infection under the in-vivo acidic vaginal environment (pH is ~4). Based on mutational studies 
and binding affinity measurements to liposomes, it has been suggested that the cationic SEVI 
peptide binds with lipid membrane to cause pH dependent membrane fusion with a maximum 
effect for pH ~4. This membrane fusion ability of SEVI was further confirmed by differential 
scanning calorimetry (DSC) experiments that showed the negative curvature induced by SEVI 
on DiPoPE lipid bilayers to form inverted hexagonal lipid structures (HII). CD and NMR 
experiments showed a partial helical structure for the mostly disordered PAP248-286 peptide in 
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the presence of lipid membrane. Based on these experimental evidences, a model was proposed 
to explain the membrane fusion process, bridging the membranes of HIV virion and target 
cells, that enhances viral infection by the disordered partial helical structural form of PAP248-286 
as illustrated in Figure 3. 
It is remarkable that the membrane fusion process can explain the effect of SEVI in the 
enhanced HIV infection to target cells. However, additional studies probing various membrane 
centric physicochemical properties would be useful to fully elucidate the roles of pH, metal 
ions such as zinc that is highly abundant in semen, anionic lipids, polysaccharides, membrane 
curvature, and lipid domains. In fact, real time monitoring of the membrane fusion process in 
liposomes that vary in lipid composition would provide a wealth of information. 
 
Intrinsically disordered PAP248-286 adapts a partial helical structure to 
promote membrane fusion 
SEVI-dependent HIV infection raised a number of very important questions that need 
to be answered to fully understand the biological process of viral infection and for the 
development of therapeutic treatments. If SEVI is effective in enhancing HIV infection via 
membrane fusion only in an aggregated form, what is the role of the secondary and tertiary 
structures of PAP248-286? What are the different types of intermediate structures formed in the 
aggregation pathway? What type of interactions initiate the formation of aggregation? How do 
these intermediate species interact with lipid membrane? Are these species located near the 
membrane surface or aggregated to form pores? Which intermediate species is effective in 
causing membrane fusion? 
To address these questions and to obtain the complete picture of SEVI’s functional role 
in the viral infection, high-resolution structure of monomeric PAP248-286 and SEVI aggregates 
are essential. Monomeric PAP248-286 has been shown to be unstructured in solution conditions, 
but CD experiments indicated the helix formation upon interaction with lipid membrane. 
However, CD experimental results are of low resolution and cannot be used to understand the 
residue specific helicity and the role of the helical structure in the membrane fusion process. To 
overcome this limitation, NMR experiments were used to investigate the structure of SEVI. 
Since SEVI induces fusion of liposomes that would pose challenges to perform NMR 
experiments to determine the high-resolution structure in a membrane environment, SDS 
micelles were used to trap the intermediated membrane bound species of SEVI. 
Two-dimensional (2D) TOCSY and 2D NOESY experiments were performed to accomplish 
the resonance assignment of the 39-residue synthetic peptide and to measure 1H-1H NOE 
restraints. Assignment of resonances in the fingerprint region of the 2D NOESY spectrum [Fig. 
4(A)], chemical shift index of alpha protons [Fig. 4(B)] and NOE intensity plot [Fig. 4(C)] are 
shown in Figure 4. The NOE distance constraints were used to determine the three-dimensional 
(3D) structure of SEVI (Fig. 5). The membrane-bound SEVI structure constitutes a short helix 
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between residues V262 and H270, a highly flexible region G248-G261 in the N-terminus, and 
a flexible region M271-Y286 with a short helix S279-L283 in the C-terminus. 
The helix forming tendency of SEVI was further investigated in 2,2,2-trifluoroethanol 
(TFE):water system as reported elsewhere (Fig. 6).40 In TFE solutions, PAP248-286 adopts a 
largely α-helical structure that differs substantially from the largely disordered structure in 
SDS micelles or in aqueous solution but is similar to the conformation PAP248-286 adopts in 
the crystal structure of the full-length protein (Fig. 5). The membrane topology determined 
using paramagnetic quenching of solvent exposed resonances by MnCl2 revealed that most of 
the residues of SEVI are solvent exposed and weakly bound to the surface of the membrane. 
This disordered and weakly membrane-bound structure of SEVI has been proposed to be 
responsible for the membrane fusion observed in in-vitro biophysical studies that enhances the 
reported dramatic enhancement of HIV viral infection. 
While the high-resolution structure is useful to explain the membrane fusion process, 
more studies are required to understand the roles of membrane components in the formation 
and stabilization of the disordered helical structure and to obtain a high-resolution view of the 
membrane fusion process. Such information would be useful to develop compounds that are 
capable of suppressing the formation of SEVI and to avoid the membrane fusion process to 
completely eliminate the SEVI dependent viral infection process. In addition, determining the 
high-resolution structure of SEVI in lipid bilayers composed of varying membrane 
composition, and in viral or host cell membrane composition, could provide more 
physiologically-relevant structure that would valuable for the development of potential drugs. 
Although this is a difficult task due to the challenges posed by the lipid membrane for 
high-resolution structural studies, the recently developed nanodiscs can be used to accomplish 
this task.41,42 In particular, the recently developed polymers that vary in charge and can form 
lipid nanodiscs would be valuable to trap the intermediate structures of SEVI in different 
membrane compositions.43 In addition, the use of “styrene-free” methacrylate polymer 
nanodiscs would enable high-throughput screening of conditions by ThT fluorescence and CD 
experiments as demonstrated recently.44 
 
Bacterial curli protein is a catalytic agent for SEVI formation 
The in-vivo observation of dramatic enhancement of HIV infection is linked to the 
amyloid aggregation of SEVI peptides. The rate of amyloid formation is typically 
nucleation-dependent and it has been shown to be very slow for SEVI amyloid formation under 
in-vitro conditions. Although SEVI formation can be speeded up by shaking under in-vitro 
conditions, the factors that influence the aggregation in in-vivo conditions are unclear. Hartman 
et al investigated the role of cross-seeding on the kinetics of amyloid aggregation of SEVI 
under in-vitro conditions.31 Since bacterial infection is likely in vagina with HIV infection, 
they specifically examined the cross-seeding effect of preformed amyloid fibers of E. coli 
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bacterial curli protein, CsgA. They reported that CsgA fibers cross-seeded by greatly 
enhancing the rate of aggregation to form SEVI fibrils. The cross-seeding was found to occur 
via an unusual mechanism. The preformed CsgA amyloid fiber seeds dramatically enhanced 
the elongation rate of SEVI. One mole % of the seed was sufficient to increase the rate by 
6-fold. On the other hand, cross-seeding with CsgA did not change the lag time unlike the 
significant reduction or complete elimination reported for other amyloid proteins. Interestingly 
the SEVI fibers obtained by cross-seeding with curli proteins were found to be longer than the 
regular SEVI fibers (Fig. 7). It is also remarkable to note the curli nucleated SEVI amyloid 
fibers exhibited enhancement of HIV infection. 
 
Inhibition of SEVI-enhanced HIV viral infection 
Since the HIV infection continues to be a devastating health issue and as shown by 
recent studies SEVI’s roles are crucial, there is significant interest in the development of 
approaches to suppress the effect of SEVI. The dramatic enhancement of HIV transmission 
by SEVI amyloid fibrils can be inhibited at various molecular levels. Some of the important 
points to be considered in the development of biochemical and biomedical approaches to 
eliminate the roles of SEVI on HIV infection are: (a) devise strategies to eliminate SEVI or 
suppress its effects; (b) eliminate HIV virions; (c) suppress membrane fusion. In this section, 
we comprehensively review the recent studies and possible methods to reduce and prevent 
HIV infectivity by semen-derived amyloid fibrils by classifying groups according to their 
actions (Fig. 8). 
 
Removal of HIV virions (Method 1) 
One simple way is to get rid of a pathogen of HIV itself using microbicidal 
compounds. Similar to the development of antimicrobial peptides that exhibit broad-spectrum 
antibacterial activties, there is considerable interest in the development of microbicidal 
compounds that show anti-viral activities. Thus, the development of topical microbicides45 is 
promising to inhibit the sexual transmission of HIV. However, microbicidal compounds 
contributing to the fast generation of drug-resistant HIV variants should be taken into 
consideration. Therefore, it is highly important to investigate the molecular mechanisms of 
action of such microbicidal compounds against HIV infection and the development of 
resistance in order to further develop more potent compounds to potentially treat the disease. 
Some of the questions that can be easily addressed include: (a) do these microbicidal 
compounds suppress the formation of SEVI amyloid aggregates? (b) do these compounds 
directly interact with SEVI aggregates to suppress their effect HIV infection? (c) are these 
compounds capable of interacting directly with the HIV virus to avoid infection? (d) can 
these compounds suppress the fusion of viral membrane with host cell membrane? 
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Development of agents to suppress HIV interaction with SEVI amyloid fibrils (Method 2) 
As mentioned earlier, SEVI amyloid aggregates interact with lipid membrane and 
promote membrane fusion, strategies to inhibit these capabilities of SEVI would be an 
effective way to reduce the SEVI’s enhancement of HIV infection. Since the aggregated 
forms of SEVI, and not the monomeric species, are potent in the enhancement of HIV 
infection, altering the chemistry of the exposed regions of SEVI can alter the efficiency of 
SEVI. For example, coating of SEVI amyloid fibrils by other molecules is expected to act 
directly on the prevention of SEVI amyloid-induced augmentation of HIV transmission. This 
idea is very simple but most likely to show relatively high efficacy against viral infection by 
blocking accessibility of HIV virions to target cells. Surfaces of SEVI amyloid fibrils are 
positively charged.32 Therefore, negatively-charged substances must be effective by 
weakening attractive electrostatic interactions between HIV virions and SEVI amyloids. 
Indeed, anionic polymers such as glycosaminoglycans and heparin diminish SEVI-mediated 
enhancement of infection.9 Aminoquinoline surfen also antagonized electrostatically the 
capability of HIV-SEVI intermolecular interactions.10 Thus, salts, inexpensive and easily 
applied to the seminal fluid of the male, may also serve as inhibitors as they are counter ions 
for positively-charged SEVI fibrils and for negatively-charged virions and cell surfaces. 
Non-polyanionic small molecules which bind to SEVI amyloid fibrils reduced SEVI 
activity. BTA-EG67 and its oligovalent derivatives46 prevented SEVI-mediated enhancement 
of HIV infection. Gallic acid showed binding ability to SEVI amyloid fibrils and decreased 
semen-mediated enhancement of HIV infection.47 Perturbation of surface electrostatics 
between cationic SEVI amyloids and HIV virions resulted in a decrease of HIV infectivity 
although the details on the physicochemical intermolecular interactions are unknown. 
Meanwhile, a D-enantiomeric peptide (RPRTRLHTHRNR), an inhibitor of Aβ(1-42) 
amyloid formation, also attenuated SEVI amyloid-boosting infection of HIV.48 Importantly, 
these studies open further opportunities that various small molecules, peptides, and proteins 
which interact with amyloid fibrils are worth testing as therapeutic agents for HIV 
acquisition. In this context, substances interacting with surfaces of either virions or cells may 
show a decrease in HIV infection even if those substance do not bind to SEVI amyloid fibrils. 
For instance, a curcumin derivative, curcumin diacetate (CurDAc), was implicated to bind to 
membrane surfaces which, thus, may prevent binding of amyloid fibrils.49 
Nanoparticles, which were generated from a polymer comprising moieties of 
amyloid-binding 6-methylbenzothiazole aniline with high affinity for SEVI amyloid fibrils 
and similar in size and shape to HIV virions, disabled SEVI-mediated HIV transmission in 
cells.50 These nanoparticles and polymers were far more efficient for inhibiting 
SEVI-enhanced HIV infection than monomeric and pentameric 6-methylbenzothiazole 
aniline, proposing a critical role of steric hindrance in the design of effective SEVI 
neutralizing agents. A very recent study suggested that a nanoparticle formulation of 
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hydrophobic polymers diminished SEVI amyloid-mediated HIV infection, and that the use of 
hydrophobic interactions to alter structures of amyloid fibrils at the level of the secondary 
structures may be an useful approach to neutralize the SEVI function.51 
 
Reverse and dissociate SEVI amyloid fibrils (Method 3) 
The presence of SEVI amyloid fibrils is a risky situation in terms of sexual 
transmission of HIV. Thus, clearance of preformed SEVI amyloids will decrease chances for 
HIV virions to contact target cells. Atomic structures of amyloid fibrils15,17 look very strong 
against exogenous stresses. However, stability of amyloid fibrils is not that high, and, rather, 
is similar to that of globular proteins,52,53 and is indeed susceptible to surrounding conditions 
such as pH, ionic strength, metal ions, solvent polarity, pressure, temperature, chemical 
denaturants, other peptides/proteins. Amyloid fibrils also showed proteolytic degradation (see 
below). Amyloid fibrils dissociated (i.e., denatured or depolymerized) to monomers by not 
only altering the temperature (cold and heat denaturation of amyloid fibrils) but also applying 
pressure or chemical denaturants (guanidine hydrochloride or urea). In most cases, decreases 
in solvent polarity by the addition of organic co-solvents such as dimethylsulfoxide and 
1,1,1,3,3,3-hexafluoroisopropanol cause denaturation of amyloid fibrils to monomers.14 As 
SEVI precursors showed pH-dependent formation of amyloid fibrils, stable and unstable at 
neutral nd acidic conditions, respectively,29 modulation of pH may be effective dissociate 
preformed SEVI amyloid fibrils. 
However, in terms of clinical application, changing to harsh environmental conditions 
in order to destruct amyloid fibrils may not be practical. Thus, treatment of seminal fluid 
containing SEVI amyloid fibrils with additives such as small molecules and proteins/peptides 
will be a better choice. Epigallocatechin-3-gallate (EGCG), the major active constituent of 
geen tea, degraded SEVI amyloid fibrils, inhibited SEVI activity, and abrogated 
semen-mediated enhancement of HIV-1 infectivity.54 NMR studies revealed the site-specific 
interactions between SEVI and EGCG and suppression of SEVI amyloid formation by EGCG 
(Fig. 9);55 specifically, EGCG binds with charged residues, primarily lysine, in the 
K251-R257 and N269-I277 regions of SEVI to form a pH dependent tight complex. Hsp104 
has been implicated as an amyloid-remodeling nanomachine,56 and showed amazing 
capability to renatures amorphous protein aggregates destruct various amyloid fibrils.57 
Castellano and colleagues modified Hsp104 to interact with the chambered protease ClpP, 
which enables coupled remodeling and degradation to irreversibly clear SEVI amyloids.58 
Similarly, prostate-specific antigen and matriptase which are proteases in seminal plasma 
degraded SEVI amyloid fibrils.59 A recent study showed disaggregation of Aβ(1-40) amyloid 
fibrils by nonhemolytic 11-residue peptide (NAVRWSLMRPF),60 which suggested the 
possible application of this short peptide for eliminating SEVI amyloid fibrils and 
peptidomimetic therapeutic agents against amyloid disease. 
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Remodeling/deformation or changes of SEVI aggregates to form HIV infection-incompetent 
strains (Method 4) 
Changes in structures and morphologies of amyloid fibrils (remodeling and/or 
deformation of amyloids) as well as transitions among different types of proteins aggregates 
such as amyloid fibrils, protofibrils, oligomers, and amorphous aggregates are often observed 
when environmental conditions change or exogenous additives are supplemented. 
Remodeling and transition of preformed amyloid fibrils of Aβ(1-40) peptides to protofibrillar 
aggregates on model membranes were observed.61 Thus, if clearance of SEVI amyloid fibrils 
is imperfect, i.e., complete denaturation to precursor proteins in soluble monomeric states, 
remodeling and deformation of SEVI amyloid fibrils to other types of amyloid fibrils which 
are incapable of elevating HIV infection by taking advantages of nature of polymorphs of 
amyloid fibrils will be alternative. In addition, conversion to non-amyloid aggregates without 
HIV virion binding capability will be also effective. 
Castellano and co-workers showed remodeling of several seminal amyloid fibrils 
including SEVI amyloids by EGCG with diminished viral infectivity in cell culture.62 Hsp104 
and an enhanced engineered variant, Hsp104A503V, directly remodel SEVI and PAP85-120 
fibrils into non-amyloid forms.58 Investigating proper conditions which cause remodeling 
and/or deformation of HIV infection-enhancing SEVI amyloids with cytotoxicity to non-toxic 
strains without HIV infection-enhancing activity. 
 
Development of proteases of SEVI precursors and inhibitors of PAP proteolysis (Method 5) 
Amyloidogenesis is remarkably context-dependent. Changes in environmental 
conditions, sole single mutation, or chemical modification alters greatly amyloidogenicity of 
precursors,63-65 which makes precursors amyloid-incompetent. SEVI precursors show high 
amyloidogenicity as a series of experimental results and prediction demonstrated.66 In 
addition, they do not take solid 3D structures and thus share similar properties of intrinsically 
disordered proteins.67 In these contexts, cleavage and degradation of SEVI precursors by 
proteases may eliminate or decelerate their amyloidogenicity and thereby inhibiting proviral 
activity. Martellini and colleagues showed a possibility of this concept by using 
subphysiological concentrations of two prominent proteases of seminal plasma, 
prostate-specific antigen and matriptase.59 These two proteases degraded physiological and 
supraphysiological concentrations of naturally occurring PAP peptides including SEVI 
precursors. 
The cleavage of amyloid precursor protein by beta secretase and gamma secretase 
produces Aβ peptides, which are thought to play important roles in Alzheimer's disease by 
forming amyloid fibrils.68-70 Thus, tremendous studies and endeavors have focused on 
establishing strategies as possible interventions against amyloid-induced neurodegenerative 
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disease. Inhibitors of beta secretase and gamma secretase have been intensively investigated 
as one of promising ways to suppress the onset of disease.71 Likewise, inhibition of 
degradation of PAP by proteolysis which produces seminal amyloid-competent fragments 
will be fundamental blocking of the enhancement of HIV viral activity. Thus, discovery and 
development of proper protease inhibitors are required. Alternatively, stabilization and 
protection of PAP by adding effective molecules may play an important role in decreasing 
activity of proteases. 
 
Increasing solubility of SEVI precursors (Method 6) 
Protein aggregation must occur over solubility limit which changes with 
environmental conditions.20,21,23 Thus, SEVI precursors under solubility conditions keep 
soluble and do not form amyloid fibrils. In these conditions, no enhancement of HIV viral 
activity is expected. Several algorithms are available to predict solubility of proteins.72 
Various factors in seminal fluid influence the solubility of SEVI precursors. For instance, a 
decrease in pH, if any, will increase solubility due to the increase in the number of positive 
charges. Indeed, SEVI precursors did not form amyloid fibrils at acidic conditions in spite of 
amyloid generation at neutral pH.29 Structural changes are also ascribed to the change in 
solubility.23 Exposures of hydrophobic regions of proteins in aqueous solution decrease the 
solubility and thereby promoting aggregation. Well-tailored additives which bind to 
hydrophobic regions and simultaneously can form hydrogen bonds with water molecules 
recover solubility. Single amino acid residues of arginine and lysine are interesting 
solubilizers for protein solutes, and can inhibit the formation of several amyloid fibrils.73 
These residues will help increase the solubility of SEVI precursors and appear to be a 
promising supplement to antiretroviral microbicides to reduce sexual transmission of HIV-1. 
 
Stabilization of SEVI precursors (Method 7) 
Maintaining of stable structures of amyloidogenic precursors which prohibits 
triggering of aggregation as the equilibrium shifts to monomers under the two-state transition 
between monomers and amyloid fibrils. Stabilization of transthyretin tetramers and insulin 
dimers in neutral pH inhibit their amyloid formation.74,75 Binding of small molecules to 
amyloidogenic SEVI precursors stabilized and inhibited amyloid fibrillation. EGCG was 
found to interact with SEVI precursors by forming a covalent bond between lysine side 
chains and EGCG (Fig. 9).55 Binding of ADS-J1 to SEVI precursors obviously inhibited 
amyloidogenesis in a dose dependent manner.76 A recent study demonstrated that brazilin, a 
natural compound that is isolated from Caesalpinia sappan, bound to SEVI precursors and 
inhibited amyloid formation at lower concentrations than EGCG.77 In addition, 
non-hemolytic 11-residue peptides inhibited the formation of Aβ(1-40) amyloid fibrils by 
interacting with the N-terminal part and the central hydrophobic cluster of Aβ(1-40).60 
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Kinetic trapping of SEVI precursors by metastability of supersaturation (Method 8) 
Protein aggregation is thermodynamically and kinetically controlled. As described 
above, aggregation initiates when proteins are over solubility. However, in reality, this 
supersaturated state (i.e., metastability of supersatuaration) kinetically traps proteins from 
nucleation to form amyloids and still keeps proteins apparently soluble.20,21,23 Thus, the lag 
time is often observed prior to burst generation of amyloid formation. Agitation and 
hydrophobic surfaces disrupt the metastability of supersatuaration and promote amyloid 
formation through nucleation. 
Thus, increases in the metastability of SEVI precursors by the addition of other 
molecules will be a useful strategy for inhibiting SEVI amyloidogenesis even over solubility 
limit by taking advantage of the kinetic nature of nucleation-dependent amyloid formation. 
Slowing down the amyloid formation without changing the concentration of residual 
monomers in equilibrium evidences the metastability of supersaturation-limited amyloid 
formation in terms of kinetics. Thus, a number of effectors which extend the lag time of 
amyloid formation would be related to the metastability of supersaturation. 
 
Amyloid capping (Method 9) 
Another intriguing method to target deleterious effects of SEVI is the 
structure/computation-based peptide inhibitor design which caps the growing end of amyloid 
fibrils with high specificity.15,16,66 This approach calculates the binding energy based on the 
steric-zipper structure of amyloid(-like) fibrils formed using hexapeptide segments of 
amyloidogenic proteins and sequences of amino acid residues,66 and was applied to the 
inhibition of SEVI amyloid formation. Amyloidogenic hexapeptide segment of PAP248-286 
(G260-N265, GGVLVN) was predicted by Zipper DB66 and inhibited SEVI (full-length 
PAP248-286) amyloid formation.15 Interestingly, a non-toxic and serum stable-designed 
heptapeptide, KR7 (KPWWPRR-NH2), blocked primarily the elongation step of insulin 
amyloid fibrils,78 suggesting the potential availability of peptide-based inhibitors for SEVI 
amyloid formation. 
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Summary and future directions 
HIV infection continues to be a major health issue, and the determination of the 
remarkable roles of SEVI amyloid is a major break-through for the development of 
compounds to eliminate HIV infection. In this review article, we have summarized the 
previous studies that reported the kinetics of amyloid aggregation of PAP peptide fragments 
and their membrane fusion properties, the effect of cross-seeding with curli bacterial amyloid 
protein, in-vivo studies on the role of SEVI amyloid aggregates, and approaches to eliminate 
the role of SEVI. Although bacterial curli protein cross-seeds the aggregation to form potent 
SEVI amyloid aggregates, more in-vitro and in-vivo studies are essential to fully evaluate the 
factors that influence the aggregation of PAP peptide fragments and the formation of SEVI 
amyloid aggregates. For example, a systematic investigation of the effects of molecular 
crowding on the formation SEVI would provide valuable insights into the mechanism 
underlying the rate of increase of HIV infection by SEVI. Since zinc is highly abundant in 
semen, and zinc is known to play very important roles in amyloid aggregation, it would be 
useful to evaluate the role of zinc and other metals on the formation of SEVI and its effect on 
HIV infection. 
While the development of small molecule compounds to suppress SEVI’s ability to 
boost HIV infection is exciting, it is important to fully investigate the role of molecular and 
structural interactions among SEVI, membrane, and HIV virion. It is worthwhile to examine 
the small molecule compounds that have already been tested for the suppression of amyloid 
aggregation and cellular toxicity of Aβ, IAPP or other amyloid proteins.79-81 Unlike the 
amyloid fibers of most other amyloid proteins, the very unique functional properties of SEVI 
fibers are exciting and related studies could provide enormous molecular insights into the 
function of a variety of other pathogens. It is also worthwhile to examine the effect of HIV 
virions on the membrane fusion effects of other amyloid proteins and the implications in 
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Figure 1. SEVI amyloid-mediated interaction of HIV with cell and general mechanism of 
amyloidogenesis. (A) Electrostatic interactions among HIV virion, SEVI amyloid fibril, and 
host cell. “−” and “+” indicate negative and positive charges, respectively. (B) 
Nucleation-dependent two-step amyloid formation is depicted. Each molecular species and 
steps during amyloid generation are represented. 
 
Figure 2. SEVI-induced aggregation of liposomes by turbidity measurements at pH 4. (A) 7:3 
POPC/POPG, (B) viral membrane composition, and (C) host cell membrane composition. (D 
and E) Photographs of 100 nm 7:3 POPC/POPG liposomes at 500 µM concentration before (D) 
and after (E) the addition of 17.5 µM PAP248-286. These figures were adopted from a previously 
published paper.28 
 
Figure 3. Illustration of SEVI-induced membrane fusion. Two views of a model α-helical 
structure of PAP248-286 showing the distribution of positively charged residues, and the predicted 
secondary structure of PAP248-286 within full-length PAP. The letter codes “C, H and E” denote a 
residue in random coil, helical, or β-sheet conformation, respectively. Figure adopted from a 
previously published paper.28 
 
Figure 4. (A) The fingerprint region of 2D 1H-1H NOESY spectrum of PAP248-286 peptide 
embedded in SDS micelles. (B and C) NOE connectivity (B) and chemical shift index of 




Figure 5. (A) NMR determined α-helical structures of PAP248-286 in SDS micelles. (B) 
Structure of PAP248-286 obtained from the crystal structure of human PAP.
82 (C) A 
representation of an ensemble of PAP248-286 conformations. Figures were adopted from a 
previously published paper.40 
 
Figure 6. High-resolution NMR structures of PAP248-286 in 30% TFE (left) and 50% TFE 
(right). Figures were adopted from a previously published paper.40 
 
Figure 7. Curli nucleation produces longer SEVI fibers. (A and B) TEM images of SEVI 
fibers formed in the absence of curli (A) and in the presence of 5 mol% CsgA (B). (C) TEM 
images of CsgA. Amyloid fibrils were grown at a concentration of 440 µM PAP248-286 at 37 
ºC under 1,400 rpm orbital shaking for 7 days. Figures were adopted from a previously 
published paper.31 
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Figure. 8. Proposed strategies of SEVI amyloid-mediated enhancement of HIV infection. 
Each strategy is indicated by M1-9 (Method 1-9 in the text). Cartoons of all molecular 
species are represented. SEVI amyloid fibrils, which are capable (red) and incapable (navy 
blue) of delivering HIV virions to target cells, are distinguished by different colors and 
shapes. 
 
Figure. 9. EGCG:PAP248-286 interaction and inhibition of SEVI amyloid formation by EGCG. 
(A) Overlaid 2D 1H-1H TOCSY spectra of PAP248-286 alone (blue) and EGCG bound to 
peptide (red, 1:1 molar ratio). (B) Specific interactions between EGCG and the side-chains of 
monomeric PAP248-286 in two regions (K251-R257 and N269-I277) of primarily charged 
residues, particularly lysine. (C) Chemical structure of EGCG. (D and E) TEM image of 
PAP248-286 incubated alone for 4 days (left) and co-incubated for 4 days with EGCG at a 1:5 
molar ratio (right) at pH 7.3 (D) and 6 (E). Figures were adopted from a previously published 
paper.55 
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Figure 1. SEVI amyloid-mediated interaction of HIV with cell and general mechanism of amyloidogenesis. (A) 
Electrostatic interactions among HIV virion, SEVI amyloid fibril, and host cell. “−” and “+” indicate negative 
and positive charges, respectively. (B) Nucleation-dependent two-step amyloid formation is depicted. Each 
molecular species and steps during amyloid generation are represented.  
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Figure 2. SEVI-induced aggregation of liposomes by turbidity measurements at pH 4. (A) 7:3 POPC/POPG, 
(B) viral membrane composition, and (C) host cell membrane composition. (D and E) Photographs of 100 
nm 7:3 POPC/POPG liposomes at 500 µM concentration before (D) and after (E) the addition of 17.5 µM 
PAP248-286. These figures were adopted from a previously published paper.28  
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Figure 3. Illustration of SEVI-induced membrane fusion. Two views of a model α-helical structure of PAP248-
286 showing the distribution of positively charged residues, and the predicted secondary structure of 
PAP248-286 within full-length PAP. The letter codes “C, H and E” denote a residue in random coil, helical, or 
β-sheet conformation, respectively. Figure adopted from a previously published paper.28  
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Figure 4. (A) The fingerprint region of 2D 1H-1H NOESY spectrum of PAP248-286 peptide embedded in SDS 
micelles. (B and C) NOE connectivity (B) and chemical shift index of alpha protons (C) of PAP248-286. 
Figures were taken from a previously published paper.40  
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Figure 5. (A) NMR determined α-helical structures of PAP248-286 in SDS micelles. (B) Structure of PAP248-
286 obtained from the crystal structure of human PAP.82 (C) A representation of an ensemble of PAP248-
286 conformations. Figures were adopted from a previously published paper.40  
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Figure 6. High-resolution NMR structures of PAP248-286 in 30% TFE (left) and 50% TFE (right). Figures 
were adopted from a previously published paper.40  
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Figure 7. Curli nucleation produces longer SEVI fibers. (A and B) TEM images of SEVI fibers formed in the 
absence of curli (A) and in the presence of 5 mol% CsgA (B). (C) TEM images of CsgA. Amyloid fibrils were 
grown at a concentration of 440 µM PAP248-286 at 37 ºC under 1,400 rpm orbital shaking for 7 days. 
Figures were adopted from a previously published paper.31  
 
 
Page 31 of 33
John Wiley & Sons
Protein Science









t   
 
 
Figure. 8. Proposed strategies of SEVI amyloid-mediated enhancement of HIV infection. Each strategy is 
indicated by M1-9 (Method 1-9 in the text). Cartoons of all molecular species are represented. SEVI amyloid 
fibrils, which are capable (red) and incapable (navy blue) of delivering HIV virions to target cells, are 
distinguished by different colors and shapes.  
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Figure. 9. EGCG:PAP248-286 interaction and inhibition of SEVI amyloid formation by EGCG. (A) Overlaid 2D 
1H-1H TOCSY spectra of PAP248-286 alone (blue) and EGCG bound to peptide (red, 1:1 molar ratio). (B) 
Specific interactions between EGCG and the side-chains of monomeric PAP248-286 in two regions (K251-
R257 and N269-I277) of primarily charged residues, particularly lysine. (C) Chemical structure of EGCG. (D 
and E) TEM image of PAP248-286 incubated alone for 4 days (left) and co-incubated for 4 days with EGCG 
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